BridgeBio Pharma (BBIO) traded lower Friday as the market focused on a near-term catalyst: the company’s first-quarter 2026 financial results and commercial updates, scheduled for May 7, 2026. With the stock up sharply from prior years on expectations for Attruby’s uptake, even a modest risk-off move can appear as investors reduce exposure ahead of the event.

The selloff comes as investors weigh the pace of Attruby’s commercial ramp against the spending required to support launch execution and the broader pipeline. A recent analyst update reduced near-term earnings expectations, reinforcing concerns that operating costs could remain elevated even if revenue momentum continues.

Key swing factors for BBIO over the next week include (1) quarterly Attruby net product revenue and prescription trends, (2) any change in full-year 2026 expense or cash-burn commentary, and (3) updated timing on planned regulatory submissions the company has previously signaled for 2026. With the May 7 report imminent, BBIO’s day-to-day price action is likely to remain sensitive to positioning and incremental estimate changes.